This page shows the latest Pemigatinib news and features for those working in and with pharma, biotech and healthcare.
Along with a priority review, pemigatinib has been awarded breakthrough status by the FDA for FGFR-mutated cholangiocarcinoma. ... Pemigatinib is also in phase 2 testing for bladder cancer and myeloid/lymphoid cancers.
Despite the first-to-market personalised medicine claim for FGFR in bladder cancer, J&J could soon be joined by Incyte, which has its own oral FGFR inhibitor, Pemigatinib, in phase
J&J could face near-term competition in the oral FGFR inhibitor category from Incyte, whose pemigatinib candidate is in phase 2 testing for bladder cancer and myeloid/lymphoid cancers, and
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...